NASA’s Joint Polar Satellite System is the nation’s advanced network of polar-orbiting environmental satellites, and a Houston joint venture is now officially working on the project. Image via nesdis.noaa.gov

A joint venture led by Houston-based space exploration company Intuitive Machines has landed a contract worth up to $719 million to work on NASA’s Joint Polar Satellite System.

Space & Technology Solutions, Intuitive Machines’ joint venture with Houston-based engineering and construction company KBR, secured the contract. Intuitive Machines supplies products and services to support robotic and human space exploration.

“Humanity’s advancement into the solar system is built upon more than a decade of innovation … , and Intuitive Machines intends to continue that legacy,” Steve Altemus, CEO of Intuitive Machines, says in a news release.

“This win is of strategic importance,” he adds, “allowing Intuitive Machines to support NASA in designing, developing, and demonstrating critical technology required to support the emerging orbital servicing market, and a validation of the company’s experience in spacecraft development, autonomous systems, and near-space communications.”

The Joint Polar Satellite System is the nation’s advanced network of polar-orbiting environmental satellites, says the National Environmental Satellite Data and Information Service. These satellites circle the earth from pole to pole and cross the equator 14 times daily.

The project launched its first satellite in 2011. By 2032, the system will feature five satellites.

The satellites measure conditions in the atmosphere, in oceans, and on land. These conditions include temperatures, moisture, clouds, rainfall, dense fog, volcanic ash, smoke and fires, snow and ice cover, and ozone.

Information collected by the satellite system supplies data to:

  • Help the National Weather Service monitor and forecast weather, including hurricanes, tornadoes, and blizzards.
  • Enable scientists and forecasters to study long-term climate trends.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.